Evidence map›Paper›PMID 37655425›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2023

Cancer Progress and Priorities: Gastric Cancer-Reply.

Priya Alagesan, Jessica C Goodwin, Katherine S Garman, Meira Epplein

Abstract readLetterComment
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Priya AlagesanDuke University School of Medicine, Durham, North Carolina.ORCID 0000-0002-2984-5539
Jessica C GoodwinDepartment of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina.ORCID 0000-0001-9545-1012
Katherine S GarmanCancer Risk, Detection, and Interception Program, Duke Cancer Institute, Durham, North Carolina.ORCID 0000-0001-7763-8465
Meira EppleinDepartment of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina.ORCID 0000-0001-5646-6430

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI Laura Fish · 1985 to 2026
$174.8M
Project 2: Racial differences in host immune response and gastric carcinogenesis: Translating underlying biology to promote gastric cancer interceptionP20CA251657 · NCI · DUKE UNIVERSITY · PI POLLAK, KATHRYN I · 2020 to 2022
$3.2M
NCI NIH HHS CA014236NCI NIH HHS CA251657NCI NIH HHS P20 CA251657NCI NIH HHS P30 CA014236
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37655425
PMCPMC10656104

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.